Regulus Therapeutics Inc., which has been struggling for years, said on July 6 that it is cutting its head count by 60%, halting enrollment in its two clinical programs, and reprioritizing its preclinical research and development. The announcement sent its stock down 52.1% to $0.35.
San Diego-based Regulus, which develops drugs targeting microRNAs, said that it will focus preclinical R&D on its hepatitis B research...